Fluoroquinolones

Infectious Disease Clinics of North America

Volumn 14, Issue 2, 2000, Pages 489-513

  O'Donnell, Judith A ^a   Gelone, Steven P ^b  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIPROFLOXACIN; CLINAFLOXACIN; DIGOXIN; ENOXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MINERAL; MORPHINE; MOXIFLOXACIN; NALIDIXIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; THEOPHYLLINE; TOSUFLOXACIN; TROVAFLOXACIN; VITAMIN; WARFARIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; TREATMENT INDICATION;

EID: 0034019311     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70260-9     Document Type: Article

References (97)

1. Anonymous Decreased susceptibility of Neisseria gonorrhoeae to fluoroquinolones- Ohio and Hawaii MMWR 43 1994 325
2. Anonymous Fluoroquinolone resistance in Neisseria gonorrhoeae —Colorado and Washington MMWR 44 1995 761
3. J.G. Bartlett R.F. Breiman L.A. Mandell Community acquired pneumonia in adults: Guidelines for management Clin Infect Dis 26 1998 811
4. C.M. Bébéar H. Renaudin A. Charron Alterations in topoisomerase IV and DNA gyrase in quinolone-resistant mutants of Mycoplasma hominis obtained in vitro Antimicrob Agents Chemother 42 1998 2304
5. D.B. Bethell T.T. Hien L.T. Phi Effects on growth of single short courses of fluoroquinolones Arch Dis Child 74 1996 44
6. J. Blaser B.B. Stone M.C. Groner Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine the importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance Antimicrob Agents Chemother 31 1987 1054
7. J.M. Blondeau Expanded activity and utility of the new fluoroquinolones: A review Clin Ther 21 1999 3
8. J.B.J. Boerama F.T.C. Willens W.J.H.M. Veheggan Ciprofloxacin versus cotrimoxazole in the treatment of patients with complicated urinary tract infections Drug Invest 1 1989 18
9. Brand H.S. van Kampen G.P.J. van der Korst J.K. Effect of nalidixic acid, pipemidic acid, and cinoxacin on chondrocyte metabolism in explants of articular cartilage Clin Exp Rheumatol 8 1990 393
10. D.M. Breines S. Quabdesselam E.Y. Ng Quinolone resistance locus nfx D of Escherichia coli is a mutant allele of the par E gene encoding a subunit of topoisomerase IV. Antimicrob Agents Chemother 41 1997 175
11. N.P. Brenwald M.J. Gill R. Wise Prevalence of a putative efflux mechanism among fluoroquinolone resistant clinical isolates of Streptococcus pneumoniae Antimicrob Agents Chemother 42 1998 2032
12. J.E. Burkhardt M.A. Hill W.W. Carlton Difloxacin reduces glycosaminoglycan synthesis in organ cultures of articular cartilage Goldberg A.M. In Vitro Toxicology: Mechanisms and New Technology 1991 Mary Ann Liebert New York 371 377
13. J.E. Burkhardt M.A. Hill W.W. Carlton Morphologic and biochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin Toxicol Pathol 20 1992 246
14. J.R. Carlson S.A. Thorton H.L. DuPont Comparative in vitro activities of 10 antimicrobial agents against bacterial enteropathogens Antimicrob Agents Chemother 24 1983 509
15. Centers for Disease Control and Prevention 1998 Guidelines for treatment of sexually transmitted diseases MMWR 47 RR-1 1998 54
16. D.K. Chen A. McGeer deAzavedo J.C. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada N Engl J Med 341 1999 233
17. W. Christ B. Esch Adverse reactions to fluoroquinolones in adults and children Infect Dis Clin Prac 3 suppl 3 1994 S168
18. W. Christ T. Lehnert Toxicity of the quinolones Siporin C. Heifetz C.L. Domagala J.M. The New Generation of Quinolones 1990 Marcel Decker New York
19. D.T.W. Chu P.B. Fernandes Structure-activity relationships of the fluoroquinolones Antimicrob Agents Chemother 33 1989 131
20. D.A. Church J.F. Kanga R.J. Kuhn Sequential ciprofloxacin therapy in pediatric cystic fibrosis: Comparative study versus ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations Pediatr Infect Dis J 16 1997 97
21. Cipro Product information 1997 Bayer Pharmaceuticals West Haven, CT
22. S.P. Cohen T.D. Hooper J.S. Wolfson Endogenous active efflux of norfloxacin in susceptible E. coli Antimicrob Agents Chemother 32 1988 1187
23. R. Davis H.M. Bryson Levofloxacin: A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy Drugs 47 1994 677
24. R.P. DiCarlo D.H. Martin Use of quinolones in sexually transmitted diseases The Quinolones 1998 Academic Press San Diego 210
25. J.M. Domagala Structure-activity and structure-side effect relationship of the quinolone antibacterials J Antimicrob Chemother 33 1994 685
26. K. Drlica Refining the fluoroquinolones ASM News 65 1999 410
27. P.H. Edelstien Antimicrobial chemotherapy for Legionnaires disease: Time for a change Ann Intern Med 15 1998 328
28. Fishman NO, Suh B, Weigel LM, et al: Three levofloxacin treatment failures of pneumococcal respiratory tract infections [abstract]. In Programs and Abstracts of the 39th International Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999
29. H. Fukuda K. Hiramatsu Primary targets of fluoroquinolones in Streptococcus pneumoniae Antimicrob Agents Chemother 43 1999 410
30. L.O. Gentry Oral antimicrobial therapy for osteomyelitis Ann Intern Med 114 1991 986
31. E.J.C. Goldstein Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, sparfloxacin, DU-6859a) in the treatment of anaerobic infections: Review of current information and efficacy Clin Infect Dis 23 suppl 1 1996 S25
32. L.J. Goodman R.M. Flielman G.M. Trenholme Comparative in vitro activity of ciprofloxacin against Campylobacter species and other bacterial enteropathogens Antimicrob Agents Chemother 25 1984 504
33. T.D. Gootz K.E. Brighty Fluoroquinolone antibacterials: SAR, mechanism of action, resistance, and clinical aspects Med Res Rev 16 1996 433
34. T.D. Gootz K.E. Brighty Chemistry and mechanism of action of quinolone antibacterials The Quinolones 1998 Academic Press San Diego 43
35. T.D. Gootz R. Zaniewski S. Haskell Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro Antimicrob Agents Chemother 40 1996 2691
36. S.M. Gordon C.J. Carlyn L.J. Doyle The emergence of Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in Cleveland, Ohio: Epidemiology and risk factors Ann Intern Med 125 1996 465
37. D.H. Hamer S.L. Gorbach Use of the quinolones for the treatment and prophylaxis of bacterial gastrointestinal infections The Quinolones 1998 Academic Press San Diego 273
38. B. Hampel R. Hullman K. Schmidt Ciprofloxacin in pediatrics: Worldwide clinical experience based on compassionate use safety report Pediatr Infect Dis J 16 1997 127
39. T. Hasburn V.J. Quagliarello Treatment of bacterial meningitis The Quinolones 1998 Academic Press San Diego 296
40. P. Heisig High-level fluoroquinolone resistance in a Salmonella typhimurium isolate due to alterations in both gyr A and gyr B genes. J Antimicrob Chemother 32 1993 367
41. E.F. Hendershot Fluoroquinolones Infect Dis Clin North Am 9 1995 715
42. T.M. Hooton R.H. Latham E.S. Way Ofloxacin versus trimethoprim-sulfamethoxazole for the treatment of acute cystitis Antimicrob Agents Chemother 33 1989 1308
43. T.M. Hooton E. Roger T. Medena Ciprofloxacin compared with doxycyline for nongonococcal urethritis: Ineffectiveness against Chlamydia trachomatis due to relapsing infection JAMA 264 1990 1418
44. T.M. Hooton W.E. Stamm The vaginal flora and urinary tract infections Mobley M.L.T. Warren J.W. Urinary Tract Infections 1996 ASM Press Washington DC 67
45. F.N. Judson B.S. Beal K.J. Tack Clinical experience of ofloxacin in sexually transmitted diseases Infection 14 1986 309
46. G.W. Kaatz S.M. Seo Mechanism of fluoroquinolone resistance in genetically-related strains of Staphylococcus aureus Antimicrob Agents Chemother 41 1997 2733
47. G.W. Kaatz S.M. Seo A. Ruble Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus Antimicrob Agents Chemother 37 1993 1086
48. M. Kato S. Takada S. Ogawara Effect of levofloxacin on glycosaminoglycan and DNA synthesis of cultured rabbit chondrocytes at concentrations inducing cartilage lesions in vivo Antimicrob Agents Chemother 39 1995 1979
49. Y. Kurumaji M. Shono Scarified photopatch testing in lomefloxacin photosensitivity Contact Dermatitis 26 1992 5
50. G.T. Lesher E.J. Froelich J.H. Gruett 1,8-naphthyridine derivatives: A new class of chemotherapy agents J Med Pharm Chem 5 1962 1063
51. D.P. Lew F.A. Waldvogel Osteomyelitis N Engl J Med 336 1997 999
52. D.P. Lew F.A. Waldvogel Quinolones and osteomyelitis: State of the art Drugs 49 suppl 2 1995 100
53. R.J. Lewis F.T.F. Tsai D.B. Wigley Molecular mechanisms of drug inhibition of DNA gyrase Bioessays 18 1996 661
54. B.A. Lipsky C.A. Baker Fluoroquinolone toxicity profiles: A review focusing on newer agents Clin Infect Dis 28 1999 352
55. Lumpkin MM: Public health advisory, Food and Drug Administration: Trovan (trovafloxacin/alatrofloxacin) [letter correspondence]. June 10, 1999
56. A. Maxwell The molecular basis of quinolone action J Antimicrob Chemother 30 1992 409
57. S. Miyame H. Nidaido T. Tanaka Active efflux of norfloxacin by Bacteroides fragilis Antimicrob Agents Chemother 42 1998 2119
58. K. Molback D.L. Baggersen F.M. Aarestrup An outbreak of multidrug resistant, quinolone resistant Salmonella enterica serotype typhimurium DT104 N Engl J Med 341 1999 1420
59. G. Montay R. Bruno J.C. Vergniol Pharmacokinetics of sparfloxacin in humans after single oral administration at doses of 200, 400, 600, and 800 mg J Clin Pharmacol 34 1994 1071
60. N.J. Moreau H. Robaux L. Baron Inhibitory effects of the quinolones on pro- and eukaryotic DNA topoisomerases I and II Antimicrob Agents Chemother 34 1990 1955
61. Muoz R. delaCampa A.G. par C subunit of DNA topoisomerase of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype Antimicrob Agents Chemother 40 1996 2252
62. S. Nakamura Mechanisms of quinolone resistance J Antimicrob Chemother 3 1997 128
63. Y. Niki K. Hashiguchi N. Okimoto Quinolone antimicrobial agents and theophylline Chest 101 1992 881
64. D.E. Nix J.J. Schentag The quinolones: An overview and comparative appraisal of their pharmacokinetics and pharmacodynamics J Clin Pharmacol 29 1988 169
65. M. Oram L.M. Fisher 4-quinolone resistance mutations in the DNA gyrase of E. coli clinical isolates identified by using PCR Antimicrob Agents Chemother 35 1991 387
66. X.S. Pan J. Ambler S. Mehtar Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae Antimicrob Agents Chemother 40 1996 2321
67. S.L. Preston G.L. Drusano A.L. Berman Pharmacodynamics of levofloxacin: A paradigm for early clinical trials JAMA 279 1998 125
68. Raxar Product information 1998 Glaxo-Wellcome Research Triangle, NC
69. T.E. Renau J.W. Gage J.A. Dever Structure-activity relationships of quinolone agents against Mycobacteria : Effect of structural modifications at the 8 position Antimicrob Agents Chemother 40 1996 2363
70. J.P. Rissing Antimicrobial therapy for chronic osteomyelitis in adults: role of the quinolones Clin Infect Dis 25 1997 1327
71. K.A. Rodvold Clinical safety profile of newer fluoroquinolones Infect Med 10 suppl 1999 41
72. A.R. Ronald M. Tutck R.G. Petersdorf A critical evaluation of nalidixic acid in urinary tract infections N Engl J Med 275 1966 1081
73. J. Sabbaj V.K. Hoagland T. Coole Norfloxacin versus cotrimoxazole in the treatment of recurrent urinary tract infections in me Scand J Infect Dis 48 suppl 1986 48
74. J.J. Schentag D.E. Nix M.H. Adelman Mathematical examination of dual individualization principles (I): Relationships between AUC above MIC and area under the inhibitory curve for cefmonoxime, ciprofloxacin, and tobramycin DICP- Ann Pharmacother 25 10 1991 1050
75. J.J. Schentag D.E. Nix A. Forrest AUIC- the universal parameter within the constraint of a reasonable dosing interval Ann Pharmacother 30 1997 1029
76. J.J. Schentag B.E. Scully Quinolones Yu V.L. Merigan T.C. Jr Barriere S. Antimicrobial Therapy and Vaccines 1999 Williams & Wilkins Baltimore 875
77. D.D. Sharpnack J.P. Mastin C.P. Childress Quinolone arthropathy in juvenile New Zealand white rabbits Lab Anim Sci 44 1994 436
78. L.L. Shen D.T.W. Chu Type II DNA topoisomerases as antibacterial targets Current Pharmaceutical Design 2 1996 195
79. K.E. Smith J.M. Besser C.W. Hedberg Quinolone-resistant Campylobacter jejuni infections in Minnesota 1992–1998 N Engl J Med 340 1999 1525
80. S.K. Spangler M.R. Jacobs P.C. Applebaum Activity of CP-99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, and piperacillin/tazobactam against 489 anaerobes Antimicrob Agents Chemother 38 1994 2471
81. S.R. Spangler M.R. Jacobs P.C. Applebaum Susceptibilities of penicillin-susceptible and resistant strains of Streptococcus pneumoniae to RP59500, vancomycin, erythromycin, PD-131628, sparfloxacin, temafloxacin, WIN 57273, ofloxacin, and ciprofloxacin Antimicrob Agents Chemother 36 1992 856
82. Springsklee M, Reiter C, Meyer JM: Safety and tolerability profile of moxifloxacin. (Abstract P0208). In Programs and Abstracts of 9th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 1999
83. R. Stahlmann C. Forster M. Shakibaei Magnesium deficiency induces joint cartilage lesions in juvenile rats which are identical to quinolone-induced arthropathy Antimicrob Agents Chemother 39 1995 2013
84. G.E. Stein N. Mummaur E.J. Glodstein A multicenter comparative trial of 3-day norfloxacin versus 10-day trimethoprim-sulfamethoxazole for the treatment of uncomplicated urinary tract infections Arch Intern Med 147 1987 1760
85. G.E. Stein Pharmacokinetics and pharmacodynamics of newer fluoroquinolones Clin Infect Dis 23 suppl 1 1996 519
86. B. Suh B. Lorber S. Gelone Development of high level quinolone resistance in Streptococcus pneumoniae during sequential quinolone therapy Drugs 58 suppl 2 1999 383
87. H. Takahashi T. Kikuchi S. Shoji Characterization of gyr A, gyr B, grl A, and grl B mutations in fluoroquinolone resistant clinical isolates of Staphylococcus aureus J Antimicrob Chemother 41 1998 49
88. H. Tomioka H. Saito K. Sato Comparative antimycobacterial activities of the newly synthesized quinolones AM-1158, sparfloxacin, and ofloxacin Antimicrob Agents Chemother 37 1993 1259
89. Trovan℞ Product information 1998 Pfizer Inc New York
90. J. Vila J. Ruiz P. Goni Quinolone resistance mutations in the topoisomerase IV par C gene of Acinetobacter baumannii J Antimicrob Chemother 39 1997 757
91. M.A. Visalli M.R. Jacobs P.C. Applebaum Activity of CP 99,219 (trovafloxacin) compared with ciprofloxacin, sparfloxacin, clinafloxacin, lomefloxacin, and cefuroxime against ten penicillin-susceptible and penicillin-resistant pneumococci by time-kill methodology J Antimicrob Chemother 37 1996 77
92. R.C. Walker The Fluoroquinolones Mayo Clin Proc 74 1999 1030
93. J.W. Warren E. Abrutyn I.K. Hebel Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women Clin Infect Dis 29 1999 745
94. A.H. Williams N. Griinebergh Ciprofloxacin and cotrimoxazole in the treatment of urinary tract infections J Antimicrob Chemother 18 suppl D 1986 107
95. H. Yamada S. Kurose-Hamada Y. Fukuda Quinolone susceptibility of norA-disrupted Staphylococcus aureus Antimicrob Agents Chemother 41 1997 2308
96. V. Zeller C. Janoir S.L. Kitzi Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae Antimicrob Agents Chemother 41 1997 1973
97. X. Zhao J.Y. Wang C. Xu Killing of Staphylococcus aureus by C-8methoxyfluoroquinolones Antimicrob Agents Chemother 42 1998 956